Predictors and Patterns of Recurrence After a Watchful Waiting Approach following Clinical Complete Response to Neoadjuvant Radiochemotherapy for Esophageal Cancer
Current Oncology · 16.03.2026 · 33 (3) · 170
DOI: 10.3390/curroncol33030170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 16.03.2026. Verfasst von Sarah Gerber und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Watchful Waiting, Neoadjuvant Therapy, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
Treatment of esophageal cancer (EC) traditionally consists of neoadjuvant radiochemotherapy (RCT) followed by resection; however, esophagectomy is associated with substantial morbidity, particularly in patients with relevant comorbidities. Therefore, a watchful waiting (WW) strategy has been increasingly adopted for patients achieving a complete response to RCT. This study aimed to identify independent predictors and recurrence patterns in EC patients managed with WW. (2)
Methods
We retrospectively analyzed all patients with potentially curable EC and complete response to RCT treated at a tertiary university hospital between 2014 and 2022. Comprehensive staging and restaging were performed using computed tomography, endoscopy with ultrasound and biopsies, and positron-emission tomography, followed by structured surveillance. Recurrence patterns and associated clinical and tumor-related factors were assessed using multivariate regression analysis. (3)
Results
Among 50 included patients, 30 (60%) developed recurrence after a median of 202 days. Patients with initially nodal-negative disease did not develop distant recurrence, whereas nodal-positive patients showed metastatic recurrence in 26% and local regrowth in 16%. (4)
Discussion
Adenocarcinoma, circumferential tumor extent greater than 50%, dysphagia, fatigue, and deterioration of general condition at restaging were independently associated with recurrence. These findings support risk-adapted surveillance and may facilitate personalized management in EC patients undergoing WW.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
- Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
- Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
ORCID-Profile: Martin D Berger, Hossein Hemmatazad, Pauline Aeschbacher, Dino Kröll, Yves Borbély
Zitieren
APA
Gerber, S., Berger, M. D., Hemmatazad, H., Aeschbacher, P., Kröll, D., Candinas, D., & Borbély, Y. (2026). Predictors and Patterns of Recurrence After a Watchful Waiting Approach following Clinical Complete Response to Neoadjuvant Radiochemotherapy for Esophageal Cancer. Current Oncology, 33(3), 170. https://doi.org/10.3390/curroncol33030170
Vancouver
Gerber S, Berger MD, Hemmatazad H, Aeschbacher P, Kröll D, Candinas D, et al. Predictors and Patterns of Recurrence After a Watchful Waiting Approach following Clinical Complete Response to Neoadjuvant Radiochemotherapy for Esophageal Cancer. Current Oncology. 2026;33(3):170. doi:10.3390/curroncol33030170
BibTeX
@article{Gerber2026,
author = {Gerber, Sarah and Berger, Martin D and Hemmatazad, Hossein and Aeschbacher, Pauline and Kröll, Dino and Candinas, Daniel and Borbély, Yves},
title = {Predictors and Patterns of Recurrence After a Watchful Waiting Approach following Clinical Complete Response to Neoadjuvant Radiochemotherapy for Esophageal Cancer},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {3},
pages = {170},
doi = {10.3390/curroncol33030170}
}
EUVIMED